- Monoclonal antibody (mAb) therapeutics are pivotal in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their specificity and efficacy have led to widespread adoption in modern medicine
- The demand for mAb therapies is significantly driven by the increasing prevalence of chronic diseases and advancements in biotechnology and genetic engineering. Techniques such as recombinant DNA technology and hybridoma methods have enhanced the development and production of monoclonal antibodies
- North America is expected to dominate the monoclonal antibody therapeutics market with market share of 45.7% due to advanced healthcare infrastructure, substantial healthcare expenditure, and strong regulatory support
- Asia-Pacific is expected to be the fastest growing region in the monoclonal antibody therapeutics market, with a market share of 30.6% during the forecast period. This growth is driven by rapid expansion in healthcare infrastructure, increasing awareness about chronic diseases, and rising demand for advanced therapeutic
- The cancer segment is expected to dominate the market with a market share of 50.5% in 2025, driven by the high prevalence of various cancers and the effectiveness of mAb therapies in targeting specific cancer cells such as those in breast cancer, lung cancer, and lymphoma
